Uncommon carbapenemase-encoding plasmids in the clinically emergent Acinetobacter pittii

J Antimicrob Chemother. 2018 Jan 1;73(1):52-56. doi: 10.1093/jac/dkx364.

Abstract

Objectives: Two carbapenemase-carrying plasmids, pLS488 (blaOXA-23) and pLS535 (blaOXA-58) from Acinetobacter pittii clinical isolates, were characterized in this study, including their ability to be transferred to Acinetobacter baumannii.

Methods: The clinical isolates were obtained from drainage fluid of a patient with biliary tract cancer and from an exudate of a patient with a hip infection (Portuguese University Hospital, 2012). Isolate characterization included antimicrobial susceptibility tests, carbapenemase production by Blue-Carba, carbapenem-hydrolysing class D β-lactamase (CHDL) gene search by PCR sequencing, ApaI-PFGE, CHDL genetic location and plasmid size by hybridization and WGS. Plasmid transfer was performed by conjugation or electroporation.

Results: pLS488 constitutes the first conjugative plasmid reported to carry a carbapenem resistance gene in A. pittii and is part of a potential new incompatibility group that might also account for the dissemination of OXA-23 in A. baumannii. pLS535 belongs to the Acinetobacter GR7 incompatibility group and presents a new scaffold for OXA-58. This plasmid lacked the machinery for conjugation, but was transferable by electroporation to A. baumannii. Both isolates, which displayed the same PFGE pattern, represent the first report of CHDL-carrying A. pittii in Portuguese hospitals.

Conclusions: Altogether, these results emphasize the importance of A. pittii, or particular A. pittii clones, as a source of resistance genes, facilitating their dissemination among different bacterial species.

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology
  • Acinetobacter* / drug effects
  • Acinetobacter* / genetics
  • Acinetobacter* / isolation & purification
  • Anti-Bacterial Agents / therapeutic use*
  • Bacterial Proteins / genetics*
  • Base Sequence
  • Carbapenems / therapeutic use*
  • Gene Transfer, Horizontal / genetics
  • Humans
  • Microbial Sensitivity Tests
  • Plasmids / genetics*
  • Portugal
  • Sequence Analysis, DNA
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Carbapenems
  • beta-lactamase OXA-23
  • beta-Lactamases
  • carbapenemase